InflaRx (IFRX) Non Operating Income (2017 - 2018)
InflaRx's (IFRX) quarterly Non Operating Income came in at $5.6 million in Q4 2018, up 132.91% year-over-year from $2.4 million in Q4 2017, and up 337.72% quarter-over-quarter from -$2.4 million in Q1 2018.
Powered by 
Analysis
InflaRx (IFRX) Non Operating Income (2017 - 2018) Analysis & Trends
InflaRx has disclosed Non Operating Income across 2 years of filings, most recently posting $5.6 million for Q4 2018.
- In Q4 2018, Non Operating Income rose 132.91% year-over-year to $5.6 million; the TTM figure through Dec 2018 stood at $4.8 million (changed N/A YoY), while the FY2019 annual figure was $3.0 million, down 6.03% from the prior year.
- Non Operating Income came in at $5.6 million for Q4 2018 at InflaRx, up from -$2.4 million in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $5.6 million in Q4 2018 to a low of -$2.4 million in Q1 2018.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | - |
| 10 | InflaRx | 139.29 Mn | -44.96 Mn | 2.74 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2018 | 5.62 Mn |
| Mar 31, 2018 | -2.36 Mn |
| Dec 31, 2017 | 2.41 Mn |
| Mar 31, 2017 | -866,175.81 |